Comparison of the novel HK-2 human renal proximal tubular cell line with the standard LLC-PK1 cell line in studying drug-induced nephrotoxicity

Canadian Journal of Physiology and Pharmacology

Volumn 88, Issue 4, 2010, Pages 448-455

  Gunness, Patrina ^a,b   Aleksa, Katarina ^a   Kosuge, Kazuhiro ^a   Ito, Shinya ^a,b   Koren, Gideon ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

HK 2; In vitro; LLC PK1; Nephrotoxicity; Renal

Indexed keywords

ACICLOVIR; CHLOROACETALDEHYDE; IFOSFAMIDE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; GLUTATHIONE;

ANIMAL CELL; ARTICLE; CELL LINE; CELL STRAIN HK 2; CELL STRAIN LLC PK1; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INDUCED DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY PROXIMAL TUBULE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SWINE; ANIMAL; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; LLC PK1 CELL LINE; METABOLISM; PROCEDURES; SPECIES DIFFERENCE; TOXICITY; TOXICITY TESTING;

ACYCLOVIR; ANIMALS; CELL LINE; CYTOCHROME P-450 CYP3A; GLUTATHIONE; HUMANS; IFOSFAMIDE; IN VITRO TECHNIQUES; KIDNEY TUBULES, PROXIMAL; LLC-PK1 CELLS; SPECIES SPECIFICITY; SWINE; TOXICITY TESTS;

EID: 77952046959     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y10-023     Document Type: Article

References (39)

1. Ahmad, T., Simmonds, M., McIver, A.G., and McGraw, M.E. 1994. Reversible renal failure in renal transplant patients receiving oral acyclovir prophylaxis. Pediatr. Nephrol. 8(4): 489-491. doi:10.1007/BF00856544. PMID:7947045.
2. Aleksa, K., Halachmi, N., Ito, S., and Koren, G. 2005a. A tubule cell model for ifosfamide nephrotoxicity. Can. J. Physiol. Pharmacol. 83(6): 499-508. doi:10.1139/y05-036. PMID:16049550.
3. Aleksa, K., Matsell, D., Krausz, K., Gelboin, H., Ito, S., and Koren, G. 2005b. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. Pediatr. Nephrol. 20(7): 872-885. doi:10.1007/s00467-004-1807-3. PMID: 15875221.
4. Becker, B.N., Fall, P., Hall, C., Milam, D., Leonard, J., Glick, A., and Schulman, G. 1993. Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature. Am. J. Kidney Dis. 22(4): 611-615. PMID:8213806.
5. Brade, W.P., Herdrich, K., and Varini, M. 1985. Ifosfamide: pharmacology, safety and therapeutic potential. Cancer Treat. Rev. 12(1): 1-47. doi:10.1016/0305-7372(85)90011-8. PMID:3896483.
6. Brigden, D., Rosling, A.E., and Woods, N.C. 1982. Renal function after acyclovir intravenous injection. Am. J. Med. 73(1A): 182-185. doi:10.1016/0002-9343(82)90087-0. PMID:6285711.
7. Carli, M., Passone, E., Perilongo, G., and Bisogno, G. 2003. Ifosfamide in pediatric solid tumors. Oncology, 65(Suppl. 2): 99-104. doi:10.1159/ 000073369. PMID:14586158.
8. Chang, T.K.H., Weber, G.F., Crespi, C.L., and Waxman, D.J. 1993. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53(23): 5629-5637. PMID:8242617.
9. Chen, C.S., Jounaidi, Y., and Waxman, D.J. 2005. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab. Dispos. 33(9): 1261-1267. doi:10.1124/dmd.105.004788. PMID:15919850.
10. de Wildt, S.N., Kearns, G.L., Leeder, J.S., and van den Anker, J.N. 1999. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet. 37(6): 485-505. doi:10.2165/00003088-199937060-00004. PMID:10628899.
11. Detrisac, C.J., Sens, M.A., Garvin, A.J., Spicer, S.S., and Sens, D.A. 1984. Tissue culture of human kidney epithelial cells of proximal tubule origin. Kidney Int. 25(2): 383-390. doi:10. 1038/ki.1984.28. PMID:6727133.
12. Eaton, D.L., and Klaassen, C.D. 2001. Principles of toxicology. In Casarett and Doull's toxicology: the basic science of poisons. 6th ed. Edited by C.D. Klaassen. McGraw-Hill Companies Inc., New York, N.Y. pp. 11-34.
13. Elion, G.B. 1983. The biochemistry and mechanism of action of acyclovir. J. Antimicrob. Chemother. 12(Suppl. B): 9-17. PMID:6313600.
14. Giannone, J.V., Li, W., Probst, M., and Okey, A.B. 1998. Prolonged depletion of AH receptor without alteration of receptor mRNA levels after treatment of cells in culture with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem. Pharmacol. 55(4): 489-497. doi:10.1016/S0006-2952(97)00493-0. PMID:9514084.
15. Hintz, M., Connor, J.D., Spector, S.A., Blum, M.R., Keeney, R.E., and Yeager, A.S. 1982. Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. Am. J. Med. 73(1A): 210-214. doi:10.1016/0002-9343(82)90093-6. PMID:6285713.
16. Jover, R., Bort, R., Gómez-Lechón, M.J., and Castell, J.V. 2001. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology, 33(3): 668-675. doi:10.1053/jhep.2001. 22176. PMID:11230748. (Pubitemid 32185230)
17. Keeney, R.E., Kirk, L.E., and Bridgen, D. 1982. Acyclovir tolerance in humans. Am. J. Med. 73(1A): 176-181. doi:10.1016/ 0002-9343(82)90086-90089 PMID:6285709.
18. Loebstein, R., and Koren, G. 1998. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics, 101(6): E8. doi:10.1542/peds.101.6.e8. PMID:9606250.
19. Lyon, A.W., Mansoor, A., and Trotter, M.J. 2002. Urinary gems: acyclovir crystalluria. Arch. Pathol. Lab. Med. 126(6): 753-754. PMID:12087974.
20. Mason, W.J., and Nickols, H.H. 2008. Images in clinical medicine. Crystalluria from acyclovir use. N. Engl. J. Med. 358(13): e14. doi:10.1056/NEJMicm066726. PMID:18367732.
21. McCune, J.S., Risler, L.J., Phillips, B.R., Thummel, K.E., Blough, D., and Shen, D.D. 2005. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab. Dispos. 33(7): 1074-1081. doi:10.1124/dmd.104. 002279. PMID:15821045.
22. Perantoni, A., and Berman, J.J. 1979. Properties of Wilms' tumor line (TUWI) and pig kidney line (LLC-PK1) typical of normal kidney tubular epithelium. In Vitro, 15(6): 446-454. doi:10. 1007/BF02618414. PMID:225262. (Pubitemid 9234690)
23. Peterslund, N.A., Larsen, M.L., and Mygind, H. 1988. Acyclovir crystalluria. Scand. J. Infect. Dis. 20(2): 225-228. doi:10.3109/ 00365548809032442. PMID:3041563.
24. Richards, D.M., Carmine, A.A., Brogden, R.N., Heel, R.C., Speight, T.M., and Avery, G.S. 1983. Acyclovir: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs, 26(5): 378-438. doi:10.2165/00003495-198326050- 00002. PMID:6315332.
25. Riddick, D.S. 1998. Drug biotransformation. In Principles of medical pharmacology. 6th ed. Edited by H. Kalant and W.H.E. Roschlau. Oxford University Press, New York, N.Y. pp. 38-54.
26. Rossi, R., Pleyer, J., Schäfers, P., Kuhn, N., Kleta, R., Deufel, T., and Jürgens, H. 1999. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med. Pediatr. Oncol. 32(3): 177-182. doi:10.1002/(SICI)1096-911X(199903) 32:3〈177::AID-MPO3〉3.0.CO;2-H. PMID:10064184.
27. Roy, P., Tretyakov, O., Wright, J., and Waxman, D.J. 1999. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab. Dispos. 27(11): 1309-1318. PMID:10534317.
28. Ryan, M.J., Johnson, G., Kirk, J., Fuerstenberg, S.M., Zager, R.A., and Torok-Storb, B. 1994. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int. 45(1): 48-57. doi:10.1038/ki.1994. 6. PMID:8127021. (Pubitemid 24045991)
29. Sawyer, M.H., Webb, D.E., Balow, J.E., and Straus, S.E. 1988. Acyclovir-induced renal failure. Clinical course and histology. Am. J. Med. 84(6): 1067-1071. doi:10.1016/0002-9343(88) 90313-0. PMID:3376977.
30. Schreiber, R., Wolpin, J., and Koren, G. 2008. Determinants of aciclovir-induced nephrotoxicity in children. Paediatr. Drugs, 10(2): 135- 139. doi:10.2165/00148581-200810020-00008. PMID:18345723.
31. Skinner, R. 2003. Chronic ifosfamide nephrotoxicity in children. Med. Pediatr. Oncol. 41(3): 190-197. doi:10.1002/mpo.10336. PMID:12868118.
32. Skinner, R., Pearson, A.D., English, M.W., Price, L., Wyllie, R.A., Coulthard, M.G., and Craft, A.W. 1996. Risk factors for ifosfamide nephrotoxicity in children. Lancet, 348(9027): 578-580. doi:10.1016/S0140- 6736(96)03480-0. PMID:8774570.
33. Sladek, N.E. 1988. Metabolism of oxazaphosphorines. Pharmacol. Ther. 37(3): 301-355. doi:10.1016/0163-7258(88)90004-6. PMID:3290910.
34. Vachvanichsanong, P., Patamasucon, P., Malagon, M., and Moore, E.S. 1995. Acute renal failure in a child associated with acyclovir. Pediatr. Nephrol. 9(3): 346-347. doi:10.1007/BF02254206. PMID:7632529.
35. Vomiero, G., Carpenter, B., Robb, I., and Filler, G. 2002. Combination of ceftriaxone and acyclovir - an underestimated nephrotoxic potential? Pediatr. Nephrol. 17(8): 633-637. doi:10. 1007/s00467-002-0867-5. PMID:12185472.
36. Wagstaff, A.J., Faulds, D., and Goa, K.L. 1994. Aciclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 47(1): 153-205. doi:10.2165/ 00003495-199447010-199500009 PMID:7510619. (Pubitemid 24032382)
37. Walker, D., Flinois, J.P., Monkman, S.C., Beloc, C., Boddy, A.V., Cholerton, S., et al. 1994. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol. 47(7): 1157-1163. doi:10.1016/0006-2952(94)90387-5. PMID:8161344.
38. Xu, H., Rajesan, R., Harper, P., Kim, R.B., Lonnerdal, B., Yang, M., et al. 2005. Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula. Br. J. Pharmacol. 146(2): 296-305. doi:10.1038/sj.bjp. 0706319. PMID:15997229.
39. Zucco, F., De Angelis, I., Testai, E., and Stammati, A. 2004. Toxicology investigations with cell culture systems: 20 years after. Toxicol. In Vitro, 18(2): 153-163. doi:10.1016/S0887-2333(03) 00147-4. PMID:14757105.